{"id":146601,"date":"2019-07-11T13:55:59","date_gmt":"2019-07-11T17:55:59","guid":{"rendered":"https:\/\/patientworthy.wpengine.com\/?p=146601&#038;preview=true&#038;preview_id=146601"},"modified":"2019-07-30T14:00:23","modified_gmt":"2019-07-30T18:00:23","slug":"une-societe-de-biotechnologie-axee-sur-les-maladies-rares-emet-des-actions","status":"publish","type":"post","link":"https:\/\/patientworthy.com\/fr\/2019\/07\/11\/une-societe-de-biotechnologie-axee-sur-les-maladies-rares-emet-des-actions\/","title":{"rendered":"Une Soci\u00e9t\u00e9 de biotechnologie ax\u00e9e sur les maladies rares \u00e9met des actions"},"content":{"rendered":"<h3><a href=\"https:\/\/www.nasdaq.com\/article\/rare-disease-biotech-fulcrum-therapeutics-sets-terms-for-77-million-ipo-cm1173033\">Il a \u00e9t\u00e9 annonc\u00e9 lundi que <em>Fulcrum Therapeutics<\/em><\/a>, une th\u00e9rapie de phase 1 mise au point par la biotechnologie et bas\u00e9e sur la r\u00e9gulation des g\u00e8nes pour les maladies rares, a annonc\u00e9 les termes de son offre publique initiale (IPO), \u00e9galement appel\u00e9e son introduction en bourse.<\/h3>\n<p>C&rsquo;est une super nouvelle ; une entreprise de biotechnologie centr\u00e9e sur les traitements des maladies rares qui ouvre son capital signifie une meilleure viabilit\u00e9 financi\u00e8re !<\/p>\n<p><a href=\"https:\/\/patientworthy.com\/2019\/04\/30\/fulcrum-therapeutics-experimental-facioscapulohumeral-muscular-dystrophy-fshd\/\">On a d\u00e9j\u00e0 \u00e9crit sur Fulcrum Therapeutics et leurs efforts pour le traitement par losmapimod contre la dystrophie musculaire facioscapulohum\u00e9rale.<\/a><\/p>\n<p>La soci\u00e9t\u00e9 bas\u00e9e dans l\u2019\u00c9tat am\u00e9ricain de Massachussets pr\u00e9voit de lever 77 millions de dollars en offrant 4,5 millions d\u2019actions \u00e0 des prix allant de 16 \u00e0 18 dollars.<\/p>\n<p><strong>Donc, tous les parieurs du march\u00e9 boursier, peut-\u00eatre gagnerez-vous une partie !<\/strong><\/p>\n<p>Fulcrum Therapeutics a \u00e9t\u00e9 fond\u00e9e en 2016 et envisage de figurer sur le Nasdaq sous le symbole FULC. Son prix devrait \u00eatre fix\u00e9 au cours de la semaine du 15 juillet 2019.<\/p>\n<p><strong>Cela laisse esp\u00e9rer que le traitement et la recherche relatifs aux maladies rares peuvent devenir de plus en plus courants. Ce mouvement est un grand pas en avant !<\/strong><\/p>\n<p>&nbsp;<\/p>\n<hr \/>\n<h4 class=\"p1\" style=\"text-align: center;\">C\u2019est notre meilleur essaie pour traduire des infos sur les maladies rares dans votre langue. Nous savons qu\u2019il est possible que cette traduction ne saisisse pas avec pr\u00e9cision toutes les nuances de votre langue maternelle, donc si vous avez des corrections ou des suggestions, veuillez nous les envoyer \u00e0 l\u2019adresse suivante : <a href=\"mailto:contribute@patientworthy.com\"><span class=\"s1\">contribute@patientworthy.com<\/span><\/a>.<\/h4>\n","protected":false},"excerpt":{"rendered":"<p>Il a \u00e9t\u00e9 annonc\u00e9 lundi que Fulcrum Therapeutics, une th\u00e9rapie de phase 1 mise au point par la biotechnologie et bas\u00e9e sur la r\u00e9gulation des g\u00e8nes pour les maladies rares, a annonc\u00e9 les termes de son offre publique initiale (IPO), \u00e9galement appel\u00e9e son introduction en bourse. C&rsquo;est une super nouvelle ; une entreprise de biotechnologie [&hellip;]<\/p>\n","protected":false},"author":107,"featured_media":146425,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[]},"categories":[13986],"tags":[14536],"_links":{"self":[{"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/posts\/146601"}],"collection":[{"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/users\/107"}],"replies":[{"embeddable":true,"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/comments?post=146601"}],"version-history":[{"count":0,"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/posts\/146601\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/media\/146425"}],"wp:attachment":[{"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/media?parent=146601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/categories?post=146601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/patientworthy.com\/fr\/wp-json\/wp\/v2\/tags?post=146601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}